Plenary Session
Vinay Prasad, MD MPH
Add to My Podcasts
Episodes
About
Reviews
Promote
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
18 minutes
Posted Jun 4, 2022 at 7:33 pm.
0:00
18:01
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint
No OS
Bad crossover
Lots to discuss here
I will be covering all the major ASCO papers on @PlenarySession
Subscribe to my substack https://vinayprasadmdmph.substack.com/
Previous
4.61 - How CDC's Vaccine Safety Missed Cases Of Myocarditis
Next
4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer
← See all 401 episodes of Plenary Session